<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="37086">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623738</url>
  </required_header>
  <id_info>
    <org_study_id>01171503</org_study_id>
    <nct_id>NCT02623738</nct_id>
  </id_info>
  <brief_title>A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-</brief_title>
  <official_title>A Phase II/III Randomized, Double-masked, Controlled, Parallel Group, Multicenter Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santen Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santen Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to determine the optimal concentration of DE-117 ophthalmic
      solution compared to the placebo ophthalmic solution and to determine if intraocular
      pressure reduction after 4 weeks of treatment with DE-117 ophthalmic solution is
      non-inferior to latanoprost ophthalmic solution 0.005%.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">304</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo ophthalmic solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eyedrop</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DE-117 ophthalmic solution low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eyedrop</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DE-117 ophthalmic solution high</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eyedrop</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latanoprost ophthalmic solution 0.005%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eyedrop</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo ophthalmic solution</intervention_name>
    <arm_group_label>Placebo ophthalmic solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DE-117 ophthalmic solution low</intervention_name>
    <arm_group_label>DE-117 ophthalmic solution low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DE-117 ophthalmic solution high</intervention_name>
    <arm_group_label>DE-117 ophthalmic solution high</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost ophthalmic solution 0.005%</intervention_name>
    <arm_group_label>Latanoprost ophthalmic solution 0.005%</arm_group_label>
    <other_name>Latanoprost</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary open angle glaucoma or ocular hypertension

        Exclusion Criteria:

          -  Patients at risk of progression of visual field loss

          -  Patients with severe visual field defect

          -  Patients with any diseases that preclude participation in this study for safety
             reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Santen Pharmaceutical Co., Ltd</last_name>
    <phone>+81-6-4802-9336</phone>
    <email>clinical@santen.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Tokyo, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 8, 2016</lastchanged_date>
  <firstreceived_date>December 3, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
